Endurant Capital Management LP Liquidia Corp Transaction History

Endurant Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$3.31 - $7.15 $1.05 Million - $2.27 Million	-317,993 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$3.29 - $8.24 $496,750 - $1.24 Million	-150,988 Reduced 32.19%	317,993 $1.13 Million
Q2 2019 Aug 14, 2019	BUY	$7.92 - $11.39 $1.85 Million - $2.66 Million	233,652 Added 99.29%	468,981 $3.75 Million
Q1 2019 May 15, 2019	BUY	$10.82 - $21.79 $2.12 Million - $4.27 Million	196,190 Added 501.26%	235,329 $2.68 Million
Q4 2018 Feb 14, 2019	BUY	$16.38 - $37.18 $246,584 - $559,707	15,054 Added 62.5%	39,139 $848,000
Q3 2018 Nov 14, 2018	BUY	$10.96 - $28.9 $263,971 - $696,056	24,085 New	24,085 $661,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.